South San Francisco, CA — March 3, 2025 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving…Original Article
FDA Approves TNKase (tenecteplase) for the Treatment of Acute Ischemic Stroke in Adults
